Despite extensive genetic and animal modelling data that support a central role for the amyloid /?-protein (Am in the genesis of Alzheimer's disease, the specific form(s) of A/? which causes injury to neurons in vivo has not been identified. In the present study, we examine the importance of soluble, pre-fibrillar assemblies of A/? as mediators of neurotoxicity. Specifically, we review the role of cell-derived SDS-stable oligomers, their blocking of hippocampal long-term potentiation in vivo and the finding that this blocking can be prevented by prior treatment of oligomerproducing cells with y-secretase inhibitors.
Introduction
Alzheimer's disease (AD) is the most common cause of progressive mental failure in aged humans and a major cause of disability and death in the developed world [l] . Two neuropathological lesions characterize the disease : intraneuronal neurofibrillary tangles, composed of the tau protein, and extracellular amyloid plaques, composed primarily of the amyloid-/? peptide (A/?). Many converging lines of evidence suggest that progressive accumulation of A/? in limbic and association cortices occurs prior to formation of plaques and tangles and initiates a complex cascade of biochemical and cellular changes that culminates in memory and cognitive impairment [2, 3] . Nevertheless, this ' amyloid hypothesis ' of AD has remained highly controversial, with some authorities proposing that A/? accumulates secondary to other unknown factors and may itself be relatively inert [4-61. Because great effort is currently being expended on the development of anti-amyloid therapeutics, it is crucial that remaining concerns about a causative role for APin Alzheimer's disease be rigorously addressed. Here we review evidence that A/? toxicity is likely to be mediated by multiple different A/? assembly forms, and that the earliest symptoms of the disease are attributable to soluble, SDS-stable low-n oligomers.
Soluble A/? and A D
Studies with synthetic A/?s have shown that fibrillar forms of A/? akin to those present in amyloidbearing neuritic plaques are neurotoxic in vitro [7-91. Such studies have supported the concept that extracellular plaques of amyloid fibrils are principally responsible for the neuronal dysfunction and loss in AD. Yet in patients dying with the disease, relatively weak correlations between the severity of dementia and the density of amyloid plaques have generally been found [lo-121. Recent studies report more robust correlations between the levels of soluble, rather than insoluble, A/? and the extent of synaptic loss and severity of cognitive impairment [ 13-1 51. T h e term soluble A/? is an operational definition, embracing all forms of A/? that remain in aqueous solution following high-speed centrifugation of physiological buffer extracts of brain [13-161. T o date, most studies of soluble A/? levels in brain have employed ELISA methods that cannot disclose the aggregation state of the species detected. However, McLean and colleagues [14] used sensitive Western blotting to detect both monomeric (4 kDa) A/? and SDS-stable oligomers ( z 8 and z 12 kDa) in the buffer-soluble fraction of human cerebral cortex. T h e dimers and trimers they described in AD brain are strikingly similar to the SDS-stable A/? oligomers we and others have detected in the lysates and conditioned media (CM) of a variety of cultured cells [17-201. T h e species that we detected in CM have been confirmed as bona fide A/? oligomers by both N-terminal radiosequencing and precipitation with A/?,,-and A/?,,-specific C-terminal antibodies [17, 20] . These oligomers migrate in denaturing gels as dimers, trimers and occasionally tetramers ( Figure 1 ). T h e pathogenic relevance of these AD oligomers is supported by the finding . Similar distributions of monomer, dimer and tnmer bands were also obtained on Tris/tricine gels of different acrylamide contents and on NuPage gels (results not shown). Note, the pH of the sample buffers and the identity of the counter ions used were different for the various gel systems employed. Throughout the figure a single arrow indicates AD monomer, a double arrow is a dimer (which frequently appears as a doublet) and T represents a trimer. (b) Detection of oligorners was unaffected by the addition of strong chaotropes to immunoprecipitates of the CM and by centrifugation of the CM at speeds (I 00000 g for I h) known t o pellet fibrils and protofibrils. Together with the results in (a) these data demonstrate that SDS-stable oligomers of AD do not arise as gel artifacts or from breakdown products of larger polymeric assemblies. (c) AD monomers but not oligomen are degraded by IDE. The fact that the oligomers are detected in the absence of AD monomer confirms that the oligomen are not abertantly migrating monomen. Moreover, the ability of IDE to selectively degrade AD monomers but not oligomers provides a useful tool to study AD oligomen in the absence of AD monomer. T h e C M of cells that stably overexpress human APP and secrete substantial amounts of AP caused an inhibition of L T P , whereas that of untransfected sister cells had no effect. Evidence that the failure of maintenance of LTP in our microinjection experiments was mediated by Ap oligomers in the CM emerged from biochemical manipulation of the sample. Immunodepletion of the C M with AP-specific antibodies prevented the block of LTP, whereas immunodepletion of APPs had no effect. Most importantly, treatment of the C M with insulindegrading enzyme (IDE), a protease that efficiently degrades A@ monomer but not oligomers (Figure l ) , did not alter the L T P effect. Taken together, these results demonstrate for the first time that a biochemically defined oligomeric assembly of naturally secreted human Ap alters [7, 8] and when injected into primate brains [53] . In addition, fibrillar Apcan block LTP in vivo [54] and can cause instantaneous and dramatic increases in the frequency of action potentials and membrane depolarizations of cultured neurons [30] . Question marks indicate uncertainty as to whether or not certain intermediates are on pathway to fibril formation. Backward an-ows denote reversibility of fibrillogenesis and changes in neuronal electrical activity. 
Cell

Therapeutic implications
AD is produced at discrete sites within cells as a monomer [37] , and it rapidly enters into equilibrium with dimers and trimers [35] , a process similar to that described for synthetic Ap [38] . It appears that a fraction of these oligomers are highly stable (via either strong hydrophobic interactions or covalent cross-links), and a portion of these is subsequently secreted [35] . These secreted oligomers of Apcan interact with neurons, altering their electrical activity and normal physiology [35] . While we focused on L T P because it is an extensively validated model of synaptic efficacy [35] , it is likely that other electrophysiological and biochemical correlates of synaptic function are also subtly altered in this paradigm. We propose that analogous synaptic changes may underlie the development of very early symptoms of A D by altering neurotransmission and initiating synaptic remodelling (Figure 2 ), akin to the early (preplaque) changes observed in Ap,,-overproducing transgenic mice [32, 33] . These effects could account for the subtle impairment of memory documented in the mouse models [34, 39, 40] and in AD subjects themselves. Thereafter, rising concentrations of soluble oligomers and monomers may allow increasing self-association, leading gradually to first diffuse and then fibrillar extracellular plaques, which could act as reservoirs for oligomers that further disrupt neuronal circuits (Figure 2 ). In view of these considerations, a particularly attractive therapeutic approach would be to selectively reduce the levels of potentially synaptotoxic oligomers. y-Secretase inhibitors can inhibit Ap oligomer formation at doses that still allow appreciable monomer production [35] and it would be anticipated that cell-penetrant inhibitors of P-secretase or other agents that reduce intracellular and/or extracellular monomer levels below the critical concentration needed for oligomerization could have a similar effect. Exploitation of the preclinical model we described above could help identify oligomer-preventing concentrations of amyloid-lowering compounds and thus minimize adverse effects. Although no physiological function has been ascribed to the AD monomer itself, marked or complete depletion of monomers could result in side effects.
Another anti-amyloid approach for treating A D is the use of peptidomimetics or other small molecules to inhibit Apaggregation [4144] . However, we have shown that A@ oligomers are already detectable in discrete intracellular vesicles known to be the sites of AD generation [35] . Because such oligomers (including stable dimers and trimers) can interfere with L T P and thus synaptic plasticity [35] , anti-aggregation agents may need to be both cell-penetrant and capable of blocking very early AD oligomerization, without adversely affecting the normal folding and oligomerization of other cellular proteins. If such molecules principally prevented the further polymerization of low-n oligomers without fully blocking initial dimerization, they could actually serve to enhance the levels of potentially synaptotoxic species. In contrast, 8-or y-secretase inhibitors, at doses such as we have identified as oligomer-blocking, would not incur this potential risk.
A more promising amyloid-directed therapy, Ap vaccination, has been shown in several studies to reduce cerebral AD levels and plaque burden, decrease amyloid-associated gliosis and neuritic dystrophy, and alleviate memory impairment in transgenic mice [34, 40, . T h e mechanism may be analogous in part to our AP-immunodepletion experiments, i.e. antibodies could bind up and help clear soluble oligomers of Ap, such that the latter are no longer present at sufficient concentrations to alter synaptic physiology. We have examined the effects of extracellular application of A@ oligomers, but we cannot exclude the possibility that the intracellular oligomers we detected also impact upon synaptic function [35] . T h e fact that antibody-mediated clearance of Ap from the brain was effective in blocking agedependent memory deficits in transgenic mice [34, 40] suggests that intraneuronal AP oligomers are less important effectors of synaptic dysfunction than their secreted counterparts. Nevertheless, the use of amyloid-lowering compounds (e.g. p-secretase and y-secretase inhibitors), which decrease both intra-and extracellular oligomer levels while allowing significant monomer production, appears particularly desirable. 
